Purple AI

www.purple-ai.co

Medical Insight+™

Clinically Validated AI Stroke Solutions

ISO 27001 Information and Security Management System

ISO 13485 Quality Management System

Medical Insight+™ BRAIN HEMORRHAGE*

KOREA MFDS

AI software that rapidly detects and localizes suspicious acute intracerebral hemorrhage on non-contrast brain CT. It highlights abnormal regions, provides probability scores, and offers ROI visualization with volume quantification. The system issues real-time alerts for critical ICH findings and supports fast, accurate clinical decision-making with automated report generation.

WORKLIST



Worklist Prioritization & Golden Time Advantage

VIEWER



AI-Driven Analysis

REPORT



Intuitive Reporting

MOBILE



Notifications & AI DICOM Viewer

---

* Approved by Korea's Ministry of Food and Drug Safety (MFDS). Volume quantification and reporting features are currently under additional MFDS review. Not cleared or approved by the US Food and Drug Administration (FDA). This software is not for clinical use in the United States and is provided for research, evaluation, and educational purposes only.

KOREA CLINICAL VALIDATION

AI assistance improved diagnostic across all clinician levels, with the greatest benefit for nonradiologists.

A multi center, randomized retrospective, crossover design, superiority, pivotal study

Brain CTs from 296 patients

146 AIH and 150 normal

By nine reviewers

- Non-radiologist physicians (n = 3)
- Board-certified radiologists (n = 3)
- Neuroradiologists (n = 3)

All Reviewers

	Without AI	With AI	P-value
Sensitivity	94.4%	97.2%	0.0017
Specificity	95.0%	96.9%	0.0376
Accuracy	94.7%	97.0%	0.0075

Each Reviewers Group



Comprehensive Hemorrhage Detect ion

All ICH subtypes, consistently high performance



KOREA MULTI-CENTER STUDY

It demonstrated meaningful gains in sensitivity and specificity for acute intracranial hemorrhage detection in a pivotal multi-center study, with consistent performance across institutions, scanner types, and hemorrhage subtypes.

Three institutions

49,841 patients

6,442 patients showed AIH

- 2,424 cases (SAH)
- 2,738 cases (SDH)
- 371 cases (EDH)
- 1,266 cases (IVH)
- 3,367 cases (ICH)

AI Performance in Patient-wise Analysis

	Accuracy	Sensitivity	Specificity	AUC
(N = 4 9 , 8 4 1)	0.977	0.944	0.982	0.992

High accuracy and robustness across a large-scale, multi-institutional dataset.

AI Sensitivity by AIH Subtype

	SAH	SDH	EDH	IVH	IPH
(N = 6,442)	0.954	0.933	0.933	0.994	0.977

AI Accuracy by Scanner

	GE	Philips	Siemens	Toshiba
(N = 4 9 , 8 4 1)	0.98	0.95-0.99	0.94-0.98	0.99

Medical Insight+™ BRAIN INFARCT*

KOREA MFDS

AI software that rapidly detects and localizes suspicious acute cerebral infarction on non-contrast brain CT. It highlights abnormal regions, provides probability scores, and offers ROI visualization with ASPECTS scoring. The system issues real-time alerts for AIS findings—including LVO, MeVO, and SVO—and supports fast, accurate clinical decision-making with automated report generation.

1



2



1 Precise AI Detection

Automatically highlights suspicious regions, assigns probability scores for the likelihood of infarction, and alerts clinicians in real time.

2 Intuitive Reporting

Generates clear, easy-to-read summary reports for rapid clinical review.

Worklist Prioritization

Urgent cases are automatically highlighted and sorted by severity.

Golden Time Advantage

Faster time-to-review for time-critical cases.

Efficiency Boost

Frees attention to the highest-risk cases first. Delivers AI-supported findings within seconds.

Automated Analysis

Detects and localizes suspected infarct regions using deep learning. Marks suspected areas and provides a probability scoring directly on CT image

PACS Integration

Connects seamlessly with existing hospital imaging systems.

---

*Approved by Korea's Ministry of Food and Drug Safety (MFDS). ASPECTS scoring and reporting features are currently under additional MFDS review. Not cleared or approved by the US Food and Drug Administration (FDA). This software is not for clinical use in the United States and is provided for research, evaluation, and educational purposes only.

Medical Insight+™ BRAIN ANEURYSM*

KOREA MFDS

AI software that rapidly detects and localizes suspected cerebral aneurysms on brain CTA. It highlights abnormal vascular regions and provides probability scores for aneurysm presence. AI-powered diagnostic support for early, accurate detection and localization of unruptured intracranial aneurysms on CTA, with precise identification of size and shape, including lesions smaller than 2 mm.







Size (mm)	AI (A)	Human (B)	Difference (A-B)
<3	75%	57%	18%p
3~5	84%	66%	18%p
5 to 10	92%	84%	8%p
> = 10	100%	99%	1%p

Worklist Prioritization

Urgent cases are automatically highlighted and sorted by severity.

Efficiency Boost

Frees attention to the highest-risk cases first. Delivers AI-supported findings within seconds.

Automated Analysis

Detects and localizes unruptured cerebral aneurysms using deep learning. Marks aneurysm locations, outlines, and diameter ranges on CTA images.

PACS Integration

Connects seamlessly with existing hospital imaging systems.

*Approved by Korea's Ministry of Food and Drug Safety (MFDS). Not cleared or approved by the US Food and Drug Administration (FDA). This software is not for clinical use in the United States and is provided for research, evaluation, and educational purposes only.

website

Contact our US Business Development Team

purpleai@purple-ai.co

Purple AI

SEOUL HQ
ADDRESS | 3rd Floor, 18, Teheran-ro 20-gil, SEOUL, KOREA
PHONE | (82) 2 - 566 - 2024
EMAIL | purpleai@purple-ai.co
WEBSITE | www.purple-ai.co